MARKET

CRIS

CRIS

Curis
NASDAQ
0.7771
-0.0245
-3.06%
Pre Market: 0.7536 -0.0235 -3.02% 04:28 06/01 EDT
OPEN
0.8014
PREV CLOSE
0.8016
HIGH
0.8330
LOW
0.7771
VOLUME
6
TURNOVER
--
52 WEEK HIGH
1.770
52 WEEK LOW
0.4700
MARKET CAP
75.08M
P/E (TTM)
-1.4063
1D
5D
1M
3M
1Y
5Y
Curis: Current report
Press release · 1d ago
Curis (CRIS) Gets a Buy from JonesTrading
TipRanks · 05/08 16:05
HC Wainwright & Co. Reiterates Curis (CRIS) Buy Recommendation
NASDAQ · 05/06 09:35
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire · 05/05 11:30
H.C. Wainwright Reaffirms Their Buy Rating on Curis (CRIS)
TipRanks · 05/05 10:25
Curis GAAP EPS of -$0.12 misses by $0.01, revenue of $2.3M misses by $0.29M
Seeking Alpha · 05/04 20:48
Curis Inc Q1 Loss decreases, but misses estimates
NASDAQ · 05/04 20:03
Curis Provides First Quarter 2023 Business Update
PR Newswire · 05/04 20:01
More
About CRIS
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Emavusertib, its lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. Erivedge is an orally bioavailable small molecule, which is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. Its other programs include CI-8993, Fimepinostat, CA-170 and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. The Company conducts its research and development programs both internally and through strategic collaborations.

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.